Durable complete response in renal cell carcinoma clinical trials
Mené sur 915 patients atteints d'un carcinome à cellules rénales de stade métastatique, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité du sunitinib et d'un traitement de première ligne combinant atézolizumab et bévacizumab (durées médianes de suivi : 15 et 24 mois)
Renal cell carcinoma is one of the most common urological cancers and its incidence is on the rise. Outcomes for patients with advanced renal cell carcinoma have improved substantially with the advent of vascular endothelial growth factor (VEGF)-targeted drugs, and with the approval of immune checkpoint blocking antibodies in the past 4 years. Although each of these drug classes has shown single drug efficacy, responses remain transient for most patients, culminating in a high proportion of patients eventually having disease progression or death
The Lancet , commentaire, 2018